These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 18025681)

  • 1. Treatment of infections caused by resistant Staphylococcus aureus.
    Anstead GM; Quinones-Nazario G; Lewis JS
    Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of infections due to resistant Staphylococcus aureus.
    Anstead GM; Cadena J; Javeri H
    Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the treatment of infections due to resistant Staphylococcus aureus.
    Anstead GM; Owens AD
    Curr Opin Infect Dis; 2004 Dec; 17(6):549-55. PubMed ID: 15640709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
    Maclayton DO; Hall RG
    Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Micek ST
    Clin Infect Dis; 2007 Sep; 45 Suppl 3():S184-90. PubMed ID: 17712745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
    Loffler CA; Macdougall C
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):961-81. PubMed ID: 18039081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with recently approved antibiotics.
    Paterson DL
    Curr Opin Pharmacol; 2006 Oct; 6(5):486-90. PubMed ID: 16904377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipopeptides and oxazolidinones--novel antibiotics in MRSA infection treatment].
    Pangercić A; Bukovski-Simonoski S; Barsić B
    Lijec Vjesn; 2010; 132 Suppl 1():11-3. PubMed ID: 20715711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B; Merckoll P; Melby KK
    Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Staphylococcus aureus and antibiotic resistance].
    Sancak B
    Mikrobiyol Bul; 2011 Jul; 45(3):565-76. PubMed ID: 21935792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient.
    Schmidt-Ioanas M; de Roux A; Lode H
    Curr Opin Crit Care; 2005 Oct; 11(5):481-6. PubMed ID: 16175036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.
    Drew RH
    Pharmacotherapy; 2007 Feb; 27(2):227-49. PubMed ID: 17253914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methicillin-resistant Staphylococcus aureus: the superbug.
    Ippolito G; Leone S; Lauria FN; Nicastri E; Wenzel RP
    Int J Infect Dis; 2010 Oct; 14 Suppl 4():S7-11. PubMed ID: 20851011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatments for methicillin-resistant Staphylococcus aureus.
    Stryjewski ME; Corey GR
    Curr Opin Crit Care; 2009 Oct; 15(5):403-12. PubMed ID: 19561492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.